Biohaven (BHVN) Assets Average (2022 - 2026)
Biohaven (BHVN) posted Assets Average of $458.9 million for Q1 2026, up 6.66% sequentially from $430.3 million in Q4 2025, and down 14.54% YoY from $537.0 million in Q1 2025.
Analysis
Biohaven (BHVN) Assets Average (2022 - 2026) Analysis & Trends
Biohaven has reported Assets Average for 5 years, with the latest figure at $458.9 million in Q1 2026.
- Quarterly Assets Average fell 14.54% year-over-year to $458.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $458.9 million (down 14.54% YoY) and the FY2025 annual result came in at $533.3 million, down 5.47% from the prior year.
- Assets Average rose to $458.9 million in Q1 2026 per BHVN's latest filing, from $430.3 million in the prior quarter.
- Over five years, Assets Average peaked at $640.2 million in Q1 2023 and troughed at $398.7 million in Q4 2022.
- A 5-year average of $498.6 million and a median of $490.2 million in 2024 frame the typical range for Assets Average.
- The widest YoY moves for Assets Average: up 25.64% in 2024, down 27.22% in 2024.
- Over 5 years, Assets Average stood at $398.7 million in 2022, then grew by 12.35% to $448.0 million in 2023, then gained by 25.64% to $562.8 million in 2024, then decreased by 23.55% to $430.3 million in 2025, then grew by 6.66% to $458.9 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $458.9 million, $430.3 million, and $479.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.22 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 3.29 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.86 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Biohaven | 2.37 Bn | 2.10 Bn | - | 418.57 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 418.57 Mn |
| Mar 31, 2026 | 458.93 Mn |
| Dec 31, 2025 | 430.29 Mn |
| Sep 30, 2025 | 479.77 Mn |
| Jun 30, 2025 | 504.68 Mn |
| Mar 31, 2025 | 537.03 Mn |
| Dec 31, 2024 | 562.82 Mn |
| Sep 30, 2024 | 546.58 Mn |
| Jun 30, 2024 | 500.59 Mn |
| Mar 31, 2024 | 465.87 Mn |
| Dec 31, 2023 | 447.97 Mn |
| Sep 30, 2023 | 444.74 Mn |
| Jun 30, 2023 | 562.63 Mn |
| Mar 31, 2023 | 640.15 Mn |
| Dec 31, 2022 | 398.71 Mn |